Solid lipid nanoparticles and nanostructured lipid carriers as novel drug delivery systems: Applications, advantages and disadvantages

Research in Pharmaceutical Sciences

Volumn 13, Issue 4, 2018, Pages 288-303

  Ghasemiyeh, Parisa ^a   Mohammadi Samani, Soliman ^b  

^a SHIRAZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b SHIRAZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Drug delivery systems; Nanoparticles; Nanostructured lipid carriers (NLCs); Routes of administration; Solid lipid nanoparticles (SLNs)

Indexed keywords

ADAPALENE; ALPHA TOCOPHEROL; AMPHOTERICIN B; ARTEMETHER; BAICALIN; BENFLUMETOL; CAFFEINE; CAPSAICIN; CYCLOSPORINE; CYPROTERONE ACETATE; DRUG CARRIER; FERULIC ACID; HYDROCHLOROTHIAZIDE; LORATADINE; LORNOXICAM; METHOTREXATE; MICONAZOLE; N ACETYLGLUCOSAMINE; NANOMATERIAL; OLANZAPINE; RESVERATROL; RETINOIC ACID; RETINOL; SILYMARIN; SIMVASTATIN; SOLID LIPID NANOPARTICLE; UBIDECARENONE; ULOBETASOL PROPIONATE; UNINDEXED DRUG; VINPOCETINE;

CLINICAL EFFECTIVENESS; DRUG ADMINISTRATION ROUTE; DRUG DELIVERY SYSTEM; DRUG FORMULATION; EMULSION; EVAPORATION; HIGH TEMPERATURE PROCEDURES; HUMAN; LOW TEMPERATURE PROCEDURES; MICROEMULSION; NONHUMAN; REVIEW; TOPICAL TREATMENT;

EID: 85049689339     PISSN: 17355362     EISSN: 17359414     Source Type: Journal    
DOI: 10.4103/1735-5362.235156     Document Type: Review

References (137)

1. MuÈller RH, Mader K, Gohla S. Solid lipid nanoparticles (SLN) for controlled drug delivery-a review of the state of the art. Eur J Pharm Biopharm. 2000;50(1):161-177.
2. Beloqui A, Solinis MA, Rodriguez-Gascon A, Almeida AJ, Preat V. Nanostructured lipid carriers: Promising drug delivery systems for future clinics. Nanomedicine. 2016;12(1):143-161.
3. Luo Y, Chen D, Ren L, Zhao X, Qin J. Solid lipid nanoparticles for enhancing vinpocetine's oral bioavailability. J Control Release. 2006;114(1):53-59.
4. Silva A, González-Mira E, García ML, Egea MA, Fonseca J, Silva R, et al. Preparation, characterization and biocompatibility studies on risperidone-loaded solid lipid nanoparticles (SLN): high pressure homogenization versus ultrasound. Colloids Surf B Biointerfaces. 2011;86(1):158-165.
5. Schwarz C, Mehnert W, Lucks JS, Müller RH. Solid lipid nanoparticles (SLN) for controlled drug delivery. I. Production, characterization and sterilization. J. Control. Release. 1994;30(1):83-96.
6. zur Mühlen A, Schwarz C, Mehnert W. Solid lipid nanoparticles (SLN) for controlled drug delivery-drug release and release mechanism. Eur J Pharm Biopharm. 1998;45(2):149-155.
7. Wang X, Chen H, Luo Z, Fu X. Preparation of starch nanoparticles in water in oil microemulsion system and their drug delivery properties. Carbohydr Polym. 2016;138:192-200.
8. Constantinides PP. Lipid microemulsions for improving drug dissolution and oral absorption: physical and biopharmaceutical aspects. Pharm Res. 1995;12(11):1561-1572.
9. Doktorovova S, Kovacevic AB, Garcia ML, Souto EB. Preclinical safety of solid lipid nanoparticles and nanostructured lipid carriers: Current evidence from in vitro and in vivo evaluation. Eur J Pharm Biopharm. 2016;108:235-252
10. Yoon G, Park JW, Yoon IS. Solid lipid nanoparticles (SLNs) and nanostructured lipid carriers (NLCs): recent advances in drug delivery. J Pharm Investig. 2013;43(5):353-362.
11. Makwana V, Jain R, Patel K, Nivsarkar M, Joshi A. Solid lipid nanoparticles (SLN) of Efavirenz as lymph targeting drug delivery system: Elucidation of mechanism of uptake using chylomicron flow blocking approach. Int J Pharm. 2015;495(1):439-446.
12. Shidhaye SS, Vaidya R, Sutar S, Patwardhan A, Kadam VJ. Solid lipid nanoparticles and nanostructured lipid carriers-innovative generations of solid lipid carriers. Curr Drug Deliv. 2008;5(4):324-231.
13. Kasongo KW, Muller RH, Walker RB. The use of hot and cold high pressure homogenization to enhance the loading capacity and encapsulation efficiency of nanostructured lipid carriers for the hydrophilic antiretroviral drug, didanosine for potential administration to paediatric patients. Pharm Dev Technol. 2012;17(3):353-362.
14. Souto EB, Müller RH. Investigation of the factors influencing the incorporation of clotrimazole in SLN and NLC prepared by hot high-pressure homogenization. J Microencapsul. 2006;23(4):377-388.
15. Chen DB, Yang TZ, Lu WL, Zhang Q. In vitro and in vivo study of two types of long-circulating solid lipid nanoparticles containing paclitaxel. Chem Pharm Bull (Tokyo). 2001;49(11):1444-1447.
16. Mojahedian MM, Daneshamouz S, Samani SM, Zargaran A. A novel method to produce solid lipid nanoparticles using n-butanol as an additional cosurfactant according to the o/w microemulsion quenching technique. Chem Phys Lipids. 2013;174:32-38.
17. Souto EB, Wissing SA, Barbosa CM, Müller RH. Development of a controlled release formulation based on SLN and NLC for topical clotrimazole delivery. Int J Pharm. 2004;278(1):71-77.
18. Pardeike J, Hommoss A, Muller RH. Lipid nanoparticles (SLN, NLC) in cosmetic and pharmaceutical dermal products. Int J Pharm. 2009;366(1-2):170-184.
19. Shah RM, Malherbe F, Eldridge D, Palombo EA, Harding IH. Physicochemical characterization of solid lipid nanoparticles (SLNs) prepared by a novel microemulsion technique. J. Colloid Interface Sci. 2014;428:286-294.
20. Gainza G, Pastor M, Aguirre JJ, Villullas S, Pedraz JL, Hernandez RM, et al. A novel strategy for the treatment of chronic wounds based on the topical administration of rhEGF-loaded lipid nanoparticles: In vitro bioactivity and in vivo effectiveness in healing-impaired db/db mice. J Control Release. 2014;185:51-61.
21. Vitorino C, Almeida A, Sousa J, Lamarche I, Gobin P, Marchand S, et al. Passive and active strategies for transdermal delivery using co-encapsulating nanostructured lipid carriers: in vitro vs. in vivo studies. Eur J Pharm Biopharm. 2014;86(2):133-144.
22. Gainza G, Bonafonte DC, Moreno B, Aguirre JJ, Gutierrez FB, Villullas S, et al. The topical administration of rhEGF-loaded nanostructured lipid carriers (rhEGF-NLC) improves healing in a porcine full-thickness excisional wound model. J Control Release. 2015;197:41-47.
23. Nnamani PO, Hansen S, Windbergs M, Lehr CM. Development of artemether-loaded nanostructured lipid carrier (NLC) formulation for topical application. Int J Pharm. 2014;477(1-2):208-217.
24. Park JH, Ban SJ, Ahmed T, Choi HS, Yoon HE, Yoon JH, et al. Development of DH-I-180-3 loaded lipid nanoparticle for photodynamic therapy. Int J Pharm. 2015;491(1-2):393-401.
25. Ferreira M, Silva E, Barreiros L, Segundo MA, Lima CSA, Reis S. Methotrexate loaded lipid nanoparticles for topical management of skin-related diseases: Design, characterization and skin permeation potential. Int J Pharm. 2016;512(1):14-21.
26. Jain AK, Jain A, Garg NK, Agarwal A, Jain A, Jain SA, et al. Adapalene loaded solid lipid nanoparticles gel: an effective approach for acne treatment. Colloids Surf B Biointerfaces. 2014;121:222-229.
27. Butani D, Yewale C, Misra A. Topical Amphotericin B solid lipid nanoparticles: Design and development. Colloids Surf B Biointerfaces. 2016;139:17-24.
28. Lohan SB, Bauersachs S, Ahlberg S, Baisaeng N, Keck CM, Muller RH, et al. Ultra-small lipid nanoparticles promote the penetration of coenzyme Q10 in skin cells and counteract oxidative stress. Eur J Pharm Biopharm. 2015;89:201-207.
29. Chen J, Wei N, Lopez-Garcia M, Ambrose D, Lee J, Annelin C, et al. Development and evaluation of resveratrol, Vitamin E, and epigallocatechin gallate loaded lipid nanoparticles for skin care applications. Eur J Pharm Biopharm. 2017;117:286-291.
30. Jenning V, Gysler A, Schäfer-Korting M, Gohla SH. Vitamin A loaded solid lipid nanoparticles for topical use: occlusive properties and drug targeting to the upper skin. Eur J Pharm Biopharm. 2000;49(3):211-218.
31. Stecova J, Mehnert W, Blaschke T, Kleuser B, Sivaramakrishnan R, Zouboulis CC, et al. Cyproterone acetate loading to lipid nanoparticles for topical acne treatment: particle characterisation and skin uptake. Pharm Res. 2007;24(5):991-1000.
32. Üner M, Karaman EF, Aydo?mu? Z. Solid lipid nanoparticles and nanostructured lipid carriers of loratadine for topical application: physicochemical stability and drug penetration through rat skin. Trop J Pharm Res. 2014;13(5):653-660.
33. Bikkad ML, Nathani AH, Mandlik SK, Shrotriya SN, Ranpise NS. Halobetasol propionate-loaded solid lipid nanoparticles (SLN) for skin targeting by topical delivery. J Liposome Res. 2014;24(2):113-123.
34. Charoenputtakhun P, Opanasopit P, Rojanarata T, Ngawhirunpat T. All-trans retinoic acid-loaded lipid nanoparticles as a transdermal drug delivery carrier. Pharm Dev Technol. 2014;19(2):164-172.
35. Desmet E, Van Gele M, Lambert J. Topically applied lipid-and surfactant-based nanoparticles in the treatment of skin disorders. Expert Opin Drug Deliv. 2017;14(1):109-122.
36. Lauterbach A, Muller-Goymann CC. Applications and limitations of lipid nanoparticles in dermal and transdermal drug delivery via the follicular route. Eur J Pharm Biopharm. 2015;97(Pt A):152-163.
37. Müller RH, Staufenbiel S, Keck CM. Lipid nanoparticles (SLN, NLC) for innovative consumer care and household products. H and PC Today. 2014;9(2):18-25.
38. Gonullu U, Uner M, Yener G, Karaman EF, Aydogmus Z. Formulation and characterization of solid lipid nanoparticles, nanostructured lipid carriers and nanoemulsion of lornoxicam for transdermal delivery. Acta Pharm. 2015;65(1):1-13.
39. Hamishehkar H, Shokri J, Fallahi S, Jahangiri A, Ghanbarzadeh S, Kouhsoltani M. Histopathological evaluation of caffeine-loaded solid lipid nanoparticles in efficient treatment of cellulite. Drug Dev Ind Pharm. 2015;41(10):1640-1646.
40. Marto J, Sangalli C, Capra P, Perugini P, Ascenso A, Goncalves L, et al. Development and characterization of new and scalable topical formulations containing N-acetyl-d-glucosamineloaded solid lipid nanoparticles. Drug Dev Ind Pharm. 2017;43(11):1792-1800.
41. Puglia C, Bonina F. Lipid nanoparticles as novel delivery systems for cosmetics and dermal pharmaceuticals. Expert Opin Drug Deliv. 2012;9(4):429-241.
42. Puglia C, Lauro MR, Offerta A, Crasci L, Micicche L, Panico AM, et al. Nanostructured lipid carriers (NLC) as vehicles for topical administration of sesamol: in vitro percutaneous absorption study and evaluation of antioxidant activity. Planta Med. 2017;83(5):398-404.
43. Puglia C, Offerta A, Tirendi GG, Tarico MS, Curreri S, Bonina F, et al. Design of solid lipid nanoparticles for caffeine topical administration. Drug Deliv. 2016;23(1):36-40.
44. Teeranachaideekul V, Chantaburanan T, Junyaprasert VB. Influence of state and crystallinity of lipid matrix on physicochemical properties and permeation of capsaicin-loaded lipid nanoparticles for topical delivery. J Drug Deliv Sci Technol. 2017;39:300-307.
45. Muller RH, Runge S, Ravelli V, Mehnert W, Thunemann AF, Souto EB. Oral bioavailability of cyclosporine: solid lipid nanoparticles (SLN) versus drug nanocrystals. Int J Pharm. 2006;317(1):82-89.
46. Sangsen Y, Wiwattanawongsa K, Likhitwitayawuid K, Sritularak B, Wiwattanapatapee R. Modification of oral absorption of oxyresveratrol using lipid based nanoparticles. Colloids Surf B Biointerfaces. 2015;131:182-190.
47. Zhuang CY, Li N, Wang M, Zhang XN, Pan WS, Peng JJ, et al. Preparation and characterization of vinpocetine loaded nanostructured lipid carriers (NLC) for improved oral bioavailability. Int J Pharm. 2010;394(1-2):179-185.
48. Shangguan M, Qi J, Lu Y, Wu W. Comparison of the oral bioavailability of silymarin-loaded lipid nanoparticles with their artificial lipolysate counterparts: implications on the contribution of integral structure. Int J Pharm. 2015;489(1-2):195-202.
49. Zhang Y, Li Z, Zhang K, Yang G, Wang Z, Zhao J, et al. Ethyl oleate-containing nanostructured lipid carriers improve oral bioavailability of trans-ferulic acid ascompared with conventional solid lipid nanoparticles. Int J Pharm. 2016;511(1):57-64.
50. Garg A, Bhalala K, Tomar DS, Wahajuddin. In-situ single pass intestinal permeability and pharmacokinetic study of developed Lumefantrine loaded solid lipid nanoparticles. Int J Pharm. 2017;516(1-2):120-30.
51. Cirri M, Mennini N, Maestrelli F, Mura P, Ghelardini C, Mannelli DCL. Development and in vivo evaluation of an innovative "Hydrochlorothiazide-in Cyclodextrins-in Solid Lipid Nanoparticles" formulation with sustained release and enhanced oral bioavailability for potential hypertension treatment in pediatrics. Int J Pharm. 2017;521(1-2):73-83.
52. Luan J, Zheng F, Yang X, Yu A, Zhai G. Nanostructured lipid carriers for oral delivery of baicalin: In vitro and in vivo evaluation. Colloids Surf. A. 2015;466:154-159.
53. Mendes AI, Silva AC, Catita JA, Cerqueira F, Gabriel C, Lopes CM. Miconazole-loaded nanostructured lipid carriers (NLC) for local delivery to the oral mucosa: improving antifungal activity. Colloids Surf B Biointerfaces. 2013;111:755-763.
54. Ranpise NS, Korabu SS, Ghodake VN. Second generation lipid nanoparticles (NLC) as an oral drug carrier for delivery of lercanidipine hydrochloride. Colloids Surf B Biointerfaces. 2014;116:81-87.
55. Ravi PR, Aditya N, Kathuria H, Malekar S, Vats R. Lipid nanoparticles for oral delivery of raloxifene: optimization, stability, in vivo evaluation and uptake mechanism. Eur J Pharm Biopharm. 2014;87(1):114-124.
56. Patil-Gadhe A, Pokharkar V. Montelukast-loaded nanostructured lipid carriers: part I oral bioavailability improvement. Eur J Pharm Biopharm. 2014;88(1):160-168.
57. Goncalves LMd, Maestrelli F, Mannelli DCL, Ghelardini C, Almeida AJ, Mura P. Development of solid lipid nanoparticles as carriers for improving oral bioavailability of glibenclamide. Eur J Pharm Biopharm. 2016;102:41-50.
58. Pandita D, Kumar S, Poonia N, Lather V. Solid lipid nanoparticles enhance oral bioavailability of resveratrol, a natural polyphenol. Food Res Int. 2014;62:1165-1174.
59. Desai PP, Date AA, Patravale VB. Overcoming poor oral bioavailability using nanoparticle formulations-opportunities and limitations. Drug Discov Today Technol. 2012;9(2):e71-e174.
60. Beloqui A, Solinis MA, Delgado A, Evora C, Isla A, Rodriguez-Gascon A. Fate of nanostructured lipid carriers (NLCs) following the oral route: design, pharmacokinetics and biodistribution. J Microencapsul. 2014;31(1):1-8.
61. Shah MK. Solid lipid nanoparticles (SLN) for oral drug delivery: an overview. J Nanomed Nanosci. 2017.
62. Muchow M, Maincent P, Müller RH. Lipid nanoparticles with a solid matrix (SLN, NLC, LDC) for oral drug delivery. Drug Dev Ind Pharm. 2008;34(12):1394-1405.
63. Nunes S, Madureira AR, Campos D, Sarmento B, Gomes AM, Pintado M, et al. Solid lipid nanoparticles as oral delivery systems of phenolic compounds: Overcoming pharmacokinetic limitations for nutraceutical applications. Crit Rev Food Sci Nutr. 2017;57(9):1863-1873.
64. Rao S, Prestidge CA. Polymer-lipid hybrid systems: merging the benefits of polymeric and lipid-based nanocarriers to improve oral drug delivery. Expert Opin Drug Deliv. 2016;13(5):691-707.
65. Leonardi A, Bucolo C, Romano GL, Platania CB, Drago F, Puglisi G, et al. Influence of different surfactants on the technological properties and in vivo ocular tolerability of lipid nanoparticles. Int J Pharm. 2014;470(1-2):133-140.
66. Attama AA, Reichl S, Müller-Goymann CC. Diclofenac sodium delivery to the eye: in vitro evaluation of novel solid lipid nanoparticle formulation using human cornea construct. International journal of pharmaceutics. 2008;355(1-2):307-313.
67. Li X, Nie Sf, Kong J, Li N, Ju CY, Pan WS. A controlled-release ocular delivery system for ibuprofen based on nanostructured lipid carriers. Int J Pharm. 2008;363(1-2):177-182.
68. Luo Q, Zhao J, Zhang X, Pan W. Nanostructured lipid carrier (NLC) coated with Chitosan Oligosaccharides and its potential use in ocular drug delivery system. Int J Pharm. 2011;403(1-2):185-191.
69. Araújo J, Gonzalez E, Egea MA, Garcia ML, Souto EB. Nanomedicines for ocular NSAIDs: safety on drug delivery. Nanomedicine. 2009;5(4):394-401.
70. Araújo J, Gonzalez-Mira E, Egea MA, Garcia ML, Souto EB. Optimization and physicochemical characterization of a triamcinolone acetonide-loaded NLC for ocular antiangiogenic applications. Int J Pharm. 2010;393(1-2):167-75.
71. Fangueiro JF, Andreani T, Egea MA, Garcia ML, Souto SB, Silva AM, et al. Design of cationic lipid nanoparticles for ocular delivery: development, characterization and cytotoxicity. Int J Pharm. 2014;461(1-2):64-73.
72. Balguri SP, Adelli GR, Janga KY, Bhagav P, Majumdar S. Ocular disposition of ciprofloxacin from topical, PEGylated nanostructured lipid carriers: Effect of molecular weight and density of poly (ethylene) glycol. Int J Pharm. 2017;529(1-2):32-43.
73. Balguri SP, Adelli GR, Majumdar S. Topical ophthalmic lipid nanoparticle formulations (SLN, NLC) of indomethacin for delivery to the posterior segment ocular tissues. Eur J Pharm Biopharm. 2016;109:224-235.
74. Chetoni P, Burgalassi S, Monti D, Tampucci S, Tullio V, Cuffini AM, et al. Solid lipid nanoparticles as promising tool for intraocular tobramycin delivery: Pharmacokinetic studies on rabbits. Eur J Pharm Biopharm. 2016;109:214-223.
75. Sánchez-López E, Espina M, Doktorovova S, Souto EB, García ML. Lipid nanoparticles (SLN, NLC): Overcoming the anatomical and physiological barriers of the eye-Part I-Barriers and determining factors in ocular delivery. Eur J Pharm Biopharm. 2017;110:70-75.
76. Sánchez-López E, Espina M, Doktorovova S, Souto EB, García ML. Lipid nanoparticles (SLN, NLC): Overcoming the anatomical and physiological barriers of the eye-Part II-Ocular drug-loaded lipid nanoparticles. Eur J Pharm Biopharm. 2017;110:58-69.
77. Liu D, Li J, Cheng B, Wu Q, Pan H. Ex Vivo and in Vivo evaluation of the effect of coating a coumarin-6-labeled nanostructured lipid carrier with chitosan-N-acetylcysteine on rabbit ocular distribution. Mol Pharm. 2017;14(8):2639-2648.
78. Almeida H, Amaral MH, Lobão P, Silva AC, Loboa JM. Applications of polymeric and lipid nanoparticles in ophthalmic pharmaceutical formulations: present and future considerations. J Pharm Pharm Sci. 2014;17(3):278-293.
79. Andrade LM, Rocha KA, De Sá FA, Marreto RN, Lima EM, Gratieri T, et al. Voriconazole-loaded nanostructured lipid carriers for ocular drug delivery. Cornea. 2016;35(6):866-871.
80. Basaran E, Demirel M, Sirmagül B, Yazan Y. Cyclosporine-A incorporated cationic solid lipid nanoparticles for ocular delivery. J Microencapsul. 2010;27(1):37-47.
81. Battaglia L, Serpe L, Foglietta F, Muntoni E, Gallarate M, Rodriguez DPA, et al. Application of lipid nanoparticles to ocular drug delivery. Expert Opin Drug Deliv. 2016;13(12):1743-1757.
82. Seyfoddin A, Shaw J, Al-Kassas R. Solid lipid nanoparticles for ocular drug delivery. Drug Deliv. 2010;17(7):467-489.
83. Souto EB, Doktorovova S, Gonzalez-Mira E, Egea MA, Garcia ML. Feasibility of lipid nanoparticles for ocular delivery of anti-inflammatory drugs. Curr Eye Res. 2010;35(7):537-552.
84. Wissing SA, Kayser O, Muller RH. Solid lipid nanoparticles for parenteral drug delivery. Adv Drug Deliv Rev. 2004;56(9):1257-1272.
85. Almeida AJ, Souto E. Solid lipid nanoparticles as a drug delivery system for peptides and proteins. Adv Drug Deliv Rev. 2007;59(6):478-490.
86. Wong HL, Bendayan R, Rauth AM, Li Y, Wu XY. Chemotherapy with anticancer drugs encapsulated in solid lipid nanoparticles. Adv Drug Deliv Rev. 2007;59(6):491-504.
87. Hommoss G, Pyo SM, Müller RH. Mucoadhesive tetrahydrocannabinol-loaded NLC-Formulation optimization and long-term physicochemical stability. Eur J Pharm Biopharm. 2017;117:408-417.
88. Muller RH, Keck CM. Challenges and solutions for the delivery of biotech drugs-a review of drug nanocrystal technology and lipid nanoparticles. J Biotechnol. 2004;113(1-3):151-170.
89. Kim JK, Park JS, Kim CK. Development of a binary lipid nanoparticles formulation of itraconazole for parenteral administration and controlled release. Int J Pharm. 2010;383(1-2):209-215.
90. Bhise K, Kashaw SK, Sau S, Iyer AK. Nanostructured lipid carriers employing polyphenols as promising anticancer agents: Quality by design (QbD) approach. Int J Pharm. 2017;526(1-2):506-515.
91. Jia L, Zhang D, Li Z, Duan C, Wang Y, Feng F, et al. Nanostructured lipid carriers for parenteral delivery of silybin: Biodistribution and pharmacokinetic studies. Colloids Surf B Biointerfaces. 2010;80(2):213-218.
92. Liu D, Liu Z, Wang L, Zhang C, Zhang N. Nanostructured lipid carriers as novel carrier for parenteral delivery of docetaxel. Colloids Surf B Biointerfaces. 2011;85(2):262-269.
93. Luan J, Zhang D, Hao L, Qi L, Liu X, Guo H, et al. Preparation, characterization and pharmacokinetics of Amoitone B-loaded long circulating nanostructured lipid carriers. Colloids and surfaces B, Biointerfaces. 2014;114:255-60.
94. Joshi MD, Müller RH. Lipid nanoparticles for parenteral delivery of actives. Eur J Pharm Biopharm. 2009;71(2):161-172.
95. Ajorlou E, Khosroushahi AY. Trends on polymerand lipid-based nanostructures for parenteral drug delivery to tumors. Cancer Chemother Pharmacol. 2017;79(2):251-265.
96. Mussi SV, Sawant R, Perche F, Oliveira MC, Azevedo RB, Ferreira LA, et al. Novel nanostructured lipid carrier co-loaded with doxorubicin and docosahexaenoic acid demonstrates enhanced in vitro activity and overcomes drug resistance in MCF-7/Adr cells. Pharm Res. 2014;31(8):1882-1892.
97. Chinsriwongkul A, Chareanputtakhun P, Ngawhirunpat T, Rojanarata T, Sila-on W, Ruktanonchai U, et al. Nanostructured lipid carriers (NLC) for parenteral delivery of an anticancer drug. AAPS PharmSciTech. 2012;13(1):150-158.
98. Wu M, Fan Y, Lv S, Xiao B, Ye M, Zhu X. Vincristine and temozolomide combined chemotherapy for the treatment of glioma: a comparison of solid lipid nanoparticles and nanostructured lipid carriers for dual drugs delivery. Drug Deliv. 2016;23(8):2720-2725.
99. Martins S, Sarmento B, Ferreira DC, Souto EB. Lipid-based colloidal carriers for peptide and protein delivery-liposomes versus lipid nanoparticles. Int J Nanomedicine. 2007;2(4):595-607.
100. Qureshi OS, Kim HS, Zeb A, Choi JS, Kim HS, Kwon JE, et al. Sustained release docetaxelincorporated lipid nanoparticles with improved pharmacokinetics for oral and parenteral administration. J Microencapsul. 2017;34(3):250-261.
101. Zeb A, Qureshi OS, Kim HS, Kim MS, Kang JH, Park JS, et al. High payload itraconazoleincorporated lipid nanoparticles with modulated release property for oral and parenteral administration. J Pharm Pharmacol. 2017;69(8):955-966.
102. Ahmadnia S, Moazeni M, Mohammadi-Samani S, Oryan A. In vivo evaluation of the efficacy of albendazole sulfoxide and albendazole sulfoxide loaded solid lipid nanoparticles against hydatid cyst. Exp Parasitol. 2013;135(2):314-319.
103. Cipolla D, Shekunov B, Blanchard J, Hickey A. Lipid-based carriers for pulmonary products: preclinical development and case studies in humans. Adv Drug Deliv Rev. 2014;75:53-80.
104. Taratula O, Kuzmov A, Shah M, Garbuzenko OB, Minko T. Nanostructured lipid carriers as multifunctional nanomedicine platform for pulmonary co-delivery of anticancer drugs and siRNA. J Control Release. 2013;171(3):349-357.
105. Pardeike J, Weber S, Haber T, Wagner J, Zarfl HP, Plank H, et al. Development of an itraconazoleloaded nanostructured lipid carrier (NLC) formulation for pulmonary application. Int J Pharm. 2011;419(1-2):329-338.
106. Patil-Gadhe A, Kyadarkunte A, Patole M, Pokharkar V. Montelukast-loaded nanostructured lipid carriers: part II pulmonary drug delivery and in vitro-in vivo aerosol performance. Eur J Pharm Biopharm. 2014;88(1):169-177.
107. Patil-Gadhe A, Pokharkar V. Pulmonary targeting potential of rosuvastatin loaded nanostructured lipid carrier: Optimization by factorial design. Int J Pharm. 2016;501(1-2):199-210.
108. Hidalgo A, Cruz A, Perez-Gil J. Barrier or carrier? Pulmonary surfactant and drug delivery. Eur J Pharm Biopharm. 2015;95(Pt A):117-127.
109. Patlolla RR, Chougule M, Patel AR, Jackson T, Tata PN, Singh M. Formulation, characterization and pulmonary deposition of nebulized celecoxib encapsulated nanostructured lipid carriers. J Control Release. 2010;144(2):233-241.
110. Nafee N, Husari A, Maurer CK, Lu C, de Rossi C, Steinbach A, et al. Antibiotic-free nanotherapeutics: ultra-small, mucus-penetrating solid lipid nanoparticles enhance the pulmonary delivery and anti-virulence efficacy of novel quorum sensing inhibitors. J Control Release. 2014;192:131-140.
111. Paranjpe M, Finke JH, Richter C, Gothsch T, Kwade A, Buttgenbach S, et al. Physicochemical characterization of sildenafil-loaded solid lipid nanoparticle dispersions (SLN) for pulmonary application. Int J Pharm. 2014;476(1-2):41-49.
112. Moreno-Sastre M, Pastor M, Esquisabel A, Sans E, Vinas M, Fleischer A, et al. Pulmonary delivery of tobramycin-loaded nanostructured lipid carriers for Pseudomonas aeruginosa infections associated with cystic fibrosis. Int J Pharm. 2016;498(1-2):263-273.
113. Zhao Y, Chang YX, Hu X, Liu CY, Quan LH, Liao YH. Solid lipid nanoparticles for sustained pulmonary delivery of Yuxingcao essential oil: Preparation, characterization and in vivo evaluation. Int J Pharm. 2017;516(1-2):364-371.
114. Makled S, Nafee N, Boraie N. Nebulized solid lipid nanoparticles for the potential treatment of pulmonary hypertension via targeted delivery of phosphodiesterase-5-inhibitor. Int J Pharm. 2017;517(1-2):312-321.
115. Islan GA, Tornello PC, Abraham GA, Duran N, Castro GR. Smart lipid nanoparticles containing levofloxacin and DNase for lung delivery. Design and characterization. Colloids Surf B Biointerfaces. 2016;143:168-176.
116. Weber S, Zimmer A, Pardeike J. Solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC) for pulmonary application: a review of the state of the art. Eur J Pharm Biopharm. 2014;86(1):7-22.
117. Pardeike J, Weber S, Zarfl HP, Pagitz M, Zimmer A. Itraconazole-loaded nanostructured lipid carriers (NLC) for pulmonary treatment of aspergillosis in falcons. Eur J Pharm Biopharm. 2016;108:269-276.
118. Kaur P, Garg T, Rath G, Murthy RS, Goyal AK. Development, optimization and evaluation of surfactant-based pulmonary nanolipid carrier system of paclitaxel for the management of drug resistance lung cancer using Box-Behnken design. Drug Deliv. 2016;23(6):1912-125.
119. Paranjpe M, Muller-Goymann CC. Nanoparticlemediated pulmonary drug delivery: a review. Int J Mol Sci. 2014;15(4):5852-5873.
120. Kaur IP, Bhandari R, Bhandari S, Kakkar V. Potential of solid lipid nanoparticles in brain targeting. J Control Release. 2008;127(2):97-109.
121. Dal Magro R, Ornaghi F, Cambianica I, Beretta S, Re F, Musicanti C, et al. ApoE-modified solid lipid nanoparticles: A feasible strategy to cross the blood-brain barrier. J Control Release. 2017;249:103-110.
122. Blasi P, Giovagnoli S, Schoubben A, Puglia C, Bonina F, Rossi C, et al. Lipid nanoparticles for brain targeting I. Formulation optimization. Int J Pharm. 2011;419(1-2):287-295.
123. Blasi P, Giovagnoli S, Schoubben A, Ricci M, Rossi C. Solid lipid nanoparticles for targeted brain drug delivery. Adv Drug Deliv Rev. 2007;59(6):454-477.
124. Blasi P, Schoubben A, Romano GV, Giovagnoli S, Michele DA, Ricci M. Lipid nanoparticles for brain targeting II. Technological characterization. Colloids Surf B Biointerfaces. 2013;110:130-137.
125. Blasi P, Schoubben A, Traina G, Manfroni G, Barberini L, Alberti PF, et al. Lipid nanoparticles for brain targeting III. Long-term stability and in vivo toxicity. Int J Pharm. 2013;454(1):316-323.
126. Gastaldi L, Battaglia L, Peira E, Chirio D, Muntoni E, Solazzi I, et al. Solid lipid nanoparticles as vehicles of drugs to the brain: current state of the art. Eur J Pharm Biopharm. 2014;87(3):433-444.
127. Montenegro L, Campisi A, Sarpietro MG, Carbone C, Acquaviva R, Raciti G, et al. In vitro evaluation of idebenone-loaded solid lipid nanoparticles for drug delivery to the brain. Drug Dev Ind Pharm. 2011;37(6):737-746.
128. Patel S, Chavhan S, Soni H, Babbar AK, Mathur R, Mishra AK, et al. Brain targeting of risperidoneloaded solid lipid nanoparticles by intranasal route. J Drug Target 2011;19(6):468-474.
129. Tosi G, Musumeci T, Ruozi B, Carbone C, Belletti D, Pignatello R, et al. The "fate" of polymeric and lipid nanoparticles for brain delivery and targeting: Strategies and mechanism of bloodbrain barrier crossing and trafficking into the central nervous system. J Drug Deliv Sci Technol. 2016;32:66-76.
130. Severino P, Andreani T, Macedo AS, Fangueiro JF, Santana MH, Silva AM, et al. Current state-of art and new trends on lipid nanoparticles (SLN and NLC) for oral drug delivery. J Drug Deliv. 2012;2012:1-10.
131. Tran TH, Ramasamy T, Truong DH, Choi HG, Yong CS, Kim JO. Preparation and characterization of fenofibrate-loaded nanostructured lipid carriers for oral bioavailability enhancement. AAPS PharmSciTech. 2014;15(6):1509-1515.
132. Khan S, Baboota S, Ali J, Khan S, Narang RS, Narang JK. Nanostructured lipid carriers: An emerging platform for improving oral bioavailability of lipophilic drugs. Int J Pharm Investig. 2015;5(4):182-191.
133. Hosseini M, Haji-Fatahaliha M, Jadidi-Niaragh F, Majidi J, Yousefi M. The use of nanoparticles as a promising therapeutic approach in cancer immunotherapy. Artif Cells Nanomed Biotechnol. 2016;44(4):1051-1061.
134. Attama AA. SLN, NLC, LDC: state of the art in drug and active delivery. Recent Pat Drug Deliv Formul. 2011;5(3):178-187.
135. Selvamuthukumar S, Velmurugan R. Nanostructured lipid carriers: a potential drug carrier for cancer chemotherapy. Lipids Health Dis. 2012;11(1):159-166.
136. Prasad D, Chauhan H. Nanotoxicity of Polymeric and Solid Lipid Nanoparticles. In:. Sutariya VB, Pathak Y, editors. Biointeractions of Nanomaterials. Florida: CRC Press; 2014. pp. 151.
137. Xiang QY, Wang MT, Chen F, Gong T, Jian YL, Zhang ZR, et al. Lung-targeting delivery of dexamethasone acetate loaded solid lipid nanoparticles. Arch Pharm Res. 2007;30(4):519-525.